JP2005040070A - ＳｔＡＲ結合蛋白質（ＳＢＰ）遺伝子の発現を抑制するオリゴヌクレオチド及び方法 - Google Patents

ＳｔＡＲ結合蛋白質（ＳＢＰ）遺伝子の発現を抑制するオリゴヌクレオチド及び方法 Download PDF

Info

Publication number
JP2005040070A
JP2005040070A JP2003278429A JP2003278429A JP2005040070A JP 2005040070 A JP2005040070 A JP 2005040070A JP 2003278429 A JP2003278429 A JP 2003278429A JP 2003278429 A JP2003278429 A JP 2003278429A JP 2005040070 A JP2005040070 A JP 2005040070A
Authority
JP
Japan
Prior art keywords
star
sbp
cells
protein
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003278429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005040070A5 (enExample
Inventor
Teruo Sugawara
照夫 菅原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Priority to JP2003278429A priority Critical patent/JP2005040070A/ja
Priority to US10/565,283 priority patent/US20070049540A1/en
Priority to EP04720753A priority patent/EP1659176A4/en
Priority to PCT/JP2004/003449 priority patent/WO2005010189A1/ja
Publication of JP2005040070A publication Critical patent/JP2005040070A/ja
Publication of JP2005040070A5 publication Critical patent/JP2005040070A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003278429A 2003-07-23 2003-07-23 ＳｔＡＲ結合蛋白質（ＳＢＰ）遺伝子の発現を抑制するオリゴヌクレオチド及び方法 Pending JP2005040070A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003278429A JP2005040070A (ja) 2003-07-23 2003-07-23 ＳｔＡＲ結合蛋白質（ＳＢＰ）遺伝子の発現を抑制するオリゴヌクレオチド及び方法
US10/565,283 US20070049540A1 (en) 2003-07-23 2004-03-15 Oligonucleotide inhibiting the expression of star-binding protein (sbp) gene and method therefor
EP04720753A EP1659176A4 (en) 2003-07-23 2004-03-15 THE EXPRESSION OF THE GENE FOR SBP (STAR-BINDING PROTEIN) DEGRADABLE OLIGONUCLEOTIDE AND METHOD THEREFOR
PCT/JP2004/003449 WO2005010189A1 (ja) 2003-07-23 2004-03-15 StAR結合蛋白質(SBP)遺伝子の発現を抑制するオリゴヌクレオチド及び方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003278429A JP2005040070A (ja) 2003-07-23 2003-07-23 ＳｔＡＲ結合蛋白質（ＳＢＰ）遺伝子の発現を抑制するオリゴヌクレオチド及び方法

Publications (2)

Publication Number Publication Date
JP2005040070A true JP2005040070A (ja) 2005-02-17
JP2005040070A5 JP2005040070A5 (enExample) 2006-08-24

Family

ID=34100781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003278429A Pending JP2005040070A (ja) 2003-07-23 2003-07-23 ＳｔＡＲ結合蛋白質（ＳＢＰ）遺伝子の発現を抑制するオリゴヌクレオチド及び方法

Country Status (4)

Country Link
US (1) US20070049540A1 (enExample)
EP (1) EP1659176A4 (enExample)
JP (1) JP2005040070A (enExample)
WO (1) WO2005010189A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165949A1 (en) * 2001-12-27 2003-09-04 Wang San Ming Genes abnormally expressed in myeloid leukemia cells with an MLL-AF9 fusion

Also Published As

Publication number Publication date
US20070049540A1 (en) 2007-03-01
WO2005010189A1 (ja) 2005-02-03
EP1659176A4 (en) 2007-02-28
EP1659176A1 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
Rosenberg et al. MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206
Yoshinouchi et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA
JP2006519008A (ja) 哺乳動物細胞の調節
KR20010099682A (ko) 단일가닥 ｄｎａ의 효소 합성
Li et al. MicroRNA-29 regulates myocardial microvascular endothelial cells proliferation and migration in association with IGF1 in type 2 diabetes
JP5666074B2 (ja) 抗炎症療法としての、アンチセンス・オリゴヌクレオチドとｓｉＲＮＡを用いてアポトーシス特異的ｅＩＦ−５Ａ（“ｅＩＦ−５Ａ”）の阻害
CN104726500B (zh) MicroRNA26b‑3p抑制剂在制备人脐带来源间充质干细胞中的应用
EP2478101A1 (en) Fra-1 target genes as drug targets for treating cancer
Pautz et al. Similar regulation of human inducible nitric-oxide synthase expression by different isoforms of the RNA-binding protein AUF1
KR102321426B1 (ko) 남성형 탈모 표적 유전자의 발현을 억제하는 비대칭 siRNA
CA2739948A1 (en) Treating hepatitis c virus infection with over-expression of microrna-196
JP2005040070A (ja) ＳｔＡＲ結合蛋白質（ＳＢＰ）遺伝子の発現を抑制するオリゴヌクレオチド及び方法
CN104884096B (zh) 人乳头瘤病毒感染相关癌症的治疗用组合物
JP7541100B2 (ja) ｓｉＲＮＡおよびその用途
Yuan et al. MicroRNA-34c regulates porcine granulosa cell function by targeting forkhead box O3a
Fedoruk-Wyszomirska et al. Highly active low magnesium hammerhead ribozyme
Holt et al. Downregulation of repressive CUP/AP-2 isoforms during adipocyte differentiation
Mcgray et al. Regulation of thrombospondin-1 expression through AU-rich elements in the 3′ UTR of the mRNA
US20110117181A1 (en) Treating hepatitis c virus infection with over-expression of microrna-196
CN105087595B (zh) 人NF-kB的核酸适配体及其应用
Takahashi et al. Dicer and positive charge of proteins decrease the stability of RNA containing the AU-rich element of GM-CSF
CN102639560A (zh) 靶向Sipa1l1的siRNA用于降低脂肪生成的用途
KR102085260B1 (ko) Ccnd3 또는 pak2 유전자의 발현을 저해하는 암을 치료하기 위한 약학적 조성물
Ren et al. Construction, modification and evaluation of apolipoprotein AI promoter-driven shRNA expression vectors against hTERT
WO2004027061A1 (ja) 抗増殖性疾患治療薬のスクリーニング方法

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090518

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090924